explore -WSS

explore

author：leisure time 2025-09-07 13:57:51 - browse：8613

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： 3 trends to watch in health tech's hiring outlook for 2024

hotspot

WSS

Addressing health care workers' trauma can help fight burnout

U.K. sequencing study surfaces new findings about tumor DNA

UnitedHealth argues against case alleging wrongful AI care denials

Making the case for fair compensation in clinical trials

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Federal weight loss drug coverage is 30 years out of date

entertainment

explore

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Supreme Court strikes down use of affirmative action

Making the case for fair compensation in clinical trials

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Medicare proposal to cover medical devices draws a mixed reaction

A single drug, study failures leave Anavex with nothing but cash

Malaria cases in Florida and Texas: Here’s what you need to know

Citing H5N1 threat, CDC urges peak flu monitoring this summer

explore

UnitedHealth argues against case alleging wrongful AI care denials

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Biogen joins immunology wave with $1.15 billion acquisition of HI

UnitedHealth argues against case alleging wrongful AI care denials

Biogen joins immunology wave with $1.15 billion acquisition of HI

Digital health: a case of mistaken identity

focus

leisure time

hotspot

leisure time